Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine

Technology in Cancer Research and Treatment

Volumn 1, Issue 4, 2002, Pages 247-256

  Kovarova, Hana ^a   Halada, Petr ^b   Man, Petr ^c   Dzubak, Petr ^d   Hajduch, Marian ^d  

^a INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BOHEMINE; CYCLIN DEPENDENT KINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CYTOSKELETON; DRUG EFFECT; DRUG SYNTHESIS; ELECTROPHORESIS; ENZYME INHIBITION; GLYCOLYSIS; LEUKEMIA CELL; LUNG CARCINOMA; MASS SPECTROMETRY; METABOLIC REGULATION; MULTIVARIATE ANALYSIS; NONHUMAN; NUCLEIC ACID SYNTHESIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEOMICS; SIGNAL TRANSDUCTION; STRESS;

EID: 0038222474     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460200100405     Document Type: Article

References (50)

1. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695 (2000).
2. Strauss, M., Lukáš, J., Bártek, J. Unrestricted cell cycling and cancer. Nature Med. 1, 1245-1246 (1995).
3. Bártek, J., Bártková, J., Lukáš, J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell. Biol. 8, 805-814 (1996).
4. Grana, X., Reddy, E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Blood 11, 211-219 (1995).
5. Ruas, M., Paters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta Rev. Cancer 1378, F115-F177 (1998).
6. Sherr, C. J., Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995).
7. Amanatullah, D. F., Reutens, B., Zafonte, B., Fu, M., Mani, S., Pestell R. G. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front. Biosci. 5, D372-D390 (2000).
8. Asp, J., Sangiorgi, L., Inerot, S. E., Lindahl, A., Molendini, L., Benassi, M. S., Picci, P. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int. J. Cancer 85, 782-786 (2000).
9. Tsujie, M., Yamamoto, H., Tomita, N., Sugita, Y., Ohue, M., Sakita, I., Tamaki, Y., Sekimoto, M., Doki, Y., Inoue, M., Matsuura, N., Monden T., Shiozaki H., Monden, M. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology 58, 126-136 (2000).
10. Tsuda, H., Yamamoto, K., Inoue T., Uchizama I., Umesaki N. The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br. J. Cancer 82, 675-682 (2000).
11. Kusume, T., Tsuda, H., Kawabata, M., Inaoue, T., Umesaki, N., Suzuki, T., Yamamoto, K. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin. Cancer Res. 5, 4152-4157 (1999).
12. Miracca, E. C., Kowalski, L. P., Naga, I. High prevalence of p16 genetic alterations in head and neck tumours. Br. J. Cancer 81, 677-683 (1999).
13. Wistuba, I. I., Albores-Saavedra, J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J. Hepatobiliary Pancreat. Surg. 6, 237-244 (1999).
14. Sausville, E. A., Johnson, J., Alley, M., Zaharevitz, D, Senderowicz, A. M. Genetic abnormalities involved in the pathogenesis of gall-bladder carcinoma. Ann. N.Y. Acad. Sci. 910, 207-221, (2000).
15. Hajdúch, M., Havlicek, L., Veselý, L., Novotný, R., Mihál, V., Strnad, M., Drug Resistance in Leukemia and Lymphoma 111, (Kaspers et al., eds.), Kluver Acad./Plenum Publishers, 341-353, NY (1999).
16. Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S. S. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771-786 (1994).
17. De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518-526 (1997).
18. Havlicek, L., Hanus, J., Vesely, J., Leclerc, S., Meijer, L., Shaw, G. Strnad, M., Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem., 40, 408-412 (1997).
19. Hajduch, M., Havlicek, L., Vesely, J., Novotny, R., Mihal, V., Strnad, M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Exp. Med. 457, 341-353 (1999).
20. Ramagli, L. S. Quantifying protein in 2-D PAGE solubization buffers. Methods Mol. Biol. 112, 99-103 (1999).
21. Shankey, T. V., Rabinovitch, P. S., Bagwell, B., Bauer, K. D, Duque, R. E, Hedley, D. W, Mayall, B. H., Wheeless, L., Cox, C. Guidelines for Implementation of Clinical DNA Cytometry, International Society for Analytical Cytology, Cytometry 14, 472-477 (1993).
22. Hochstrasser, D. F., Frutiger, S., Paquet, N., Bairoch, A., Ravier, F., Pasquali, C., Sanchez, J.-C., Tissot, J.-D., Bjellquist, B., Vargas, R., Appel, R. D., Hughes, G. J. Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis 13, 992-1001 (1992).
23. Bjellquist, B., Pasquali, C., Ravier, F., Sanchez, J.-C., Hochstrasser, D. F. A nonlinear wide-range immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14, 1357-1365 (1993).
24. Eckerskorn, C., Jungblut P., Mewes, W., Klose, J., Lottspeuch, F. Identification of mouse brain proteins after two-dimensional electrophotesis and electroblotting by microsequence analysis and amino acid composition analysis. Electrophoresis 12, 830-838 (1988).
25. Manly, B. F. J., Multivariate Statistical Methods: A Primer, Chapman and Hall, London, 59-71, NY (1986).
26. http://129.85.19.192/profound_bin/webProFound.exe
27. Meijer, L., Borgne, A, Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J.G., Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527-536 (1997).
28. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S. H., Lockhart, D. J., Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
29. Kovarova, H., Hajduch, M., Korinkova, G., Halada, P., Krupickova, S., Gouldsworthy, A., Zhelev, N., Strnad, M. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis 21, 3757-3764 (2000).
30. Mihal, V., Noskova, V., Gojova, L., Strnad, M., Janostakova, A., Hajduch, M. Cytotoxic activity of the cyclin dependent kinase inhibitor, Bohemine, in primary tumor cells. Blood 98, 4414 (2001).
31. Lu, H., Forbes, R. A., Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effects in cancerogenesis. J. Biol. Chem., in press (2002).
32. Giatromanolaki, A., Harris, A. L. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res. 21, 4317-4324 (2001).
33. Boren, J., Cascante, M., Marin, S., Comin-Anduix, B., Centelles, J. J., Lim, S., Bassilian, S., Ahmed, S., Lee, W. N., Boros, L. G. Gleevec (STI571) influences matabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumour cells. J. Biol. Chem. 276, 37747-53 (2001).
34. Cheng, A. J., Chiu, D. T., See, L. C., Liao, C. T, Chen, I. H., Chang, J. T. Poor prognosis in nasospharyngeal cancer patients with low glucose-6-phosphate-dehydrogenase activity. Jpn. J. Cancer. Res. 92, 576-81 (2001).
35. Kang, J. S., Calvo, B. F., Maygarden, S. J., Caskey, L. S., Mohler, J. L., Ornstein, D. K. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin. Cancer Res. 8, 117-23 (2002).
36. rd. Loss of annexin I correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 60, 6293-7 (2000).
37. Sinha, P., Hutter, G., Kottgen, E., Dietel, M., Schadendorf, D., Lage, H. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cellls. J. Biochem. Biophys. Methods 37, 105-16 (1998).
38. Wu, Y. L., Jiang, X. R., Lillington, D. M., Newland, A. C., Kelsey, S. M. Upregulation of lipocortin 1 inhibits tumour necrosis-induced apoptosis in human leukaemic cells: a possible mechanism of resistance to immune surveillance. Br. J. Haematol. 111, 807-16 (2000).
39. Han, E. K., Tahir, S. K., Cherian, S. P., Collins, N., Ng, S. C. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer 83, 83-8 (2000).
40. Sinha, P., Hutter, G., Kottgen, E., Dietel, M., Schdendorf, D., Lage, H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 20, 2961-2969 (1999).
41. Frame, M. C., Brunton, V. G. Advances in Rho-dependent actin regulation and oncogenic transformation. Curr. Opin. Genet. Dev. 12, 36-43 (2002).
42. Rosenblum, M. D., Shivers, R. R. "Rings" of F-actin form around the nucleus in cultured human MCF7 adenocarcinomacells upon exposure to both taxol and taxorete. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 125, 121-31 (2002).
43. Bauer, K., Kratzer, M., Otte, M., deQuintana, K. L., Hagmann, J., Arnold, G. J., Eckerskorn, C., Lottspeich, F., Siess, W. Human CLP36, a PDZ-domain and LIM-domain protein, binds to alpha actinin-1 and associates with actin filaments and stress fibers in activated platelets and endothelial cells. Blood 96, 4236-45 (2000).
44. Bini, L., Magi, B., Marzocchi, B., Arcuri, F., et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18, 2832-41 (1997).
45. Cornford, P. A., Dodson, A. R., Parsons, K. F., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60, 7099-7105 (2000)
46. Thomas, M. L., Samant, U. C., Deshpande, R. K, Chiplunkar, S. V. gammadelta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol. Immunother. 48, 653-659 (2000).
47. Piselli, P., Vendeti, S., Vismara, D., Cicconi, R., et al. Different expression of CD44, ICAM-1, and HSP60 on primary tumor and metastases of a human pancreatic carcinoma growing in scid mice. Anticancer Res. 20, 825-31 (2000).
48. Harris, R. A., Yang, A., Stein, R. C., Lucy, K., Brusten, L., Herath, A., Parekh, R., Waterfield, M. D., O'Hare, M. J., Neville, M. A., Page, M. J., Zvelebil, M. J. Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics 2, 212-223 (2002).
49. Zhang, Q. H., Ye, M., Wu, X. Y., Ren, S. X., Zhao, C. J., Fu, G., Shen, Y., Fan, H. Y. et al. Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 10, 1546-1560 (2000).
50. Wang, Z., Morrow, J. S. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J. Biol. Chem. 275, 8062-71 (2000).